Faeth Therapeutics, Inc.
FTH
$32.34
$3.7913.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.02M | 27.49M | 11.33M | 11.37M | 12.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 198.82M | 185.64M | 22.29M | 24.65M | 27.63M |
| Operating Income | -198.82M | -185.64M | -22.29M | -24.65M | -27.63M |
| Income Before Tax | -195.53M | -184.46M | -21.09M | -24.14M | -26.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -195.53 | -184.46 | -21.09 | -24.14 | -26.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -195.53M | -184.46M | -21.09M | -24.14M | -26.82M |
| EBIT | -198.82M | -185.64M | -22.29M | -24.65M | -27.63M |
| EBITDA | -198.70M | -185.51M | -22.15M | -24.22M | -26.89M |
| EPS Basic | -141.65 | -142.73 | -16.73 | -19.16 | -21.31 |
| Normalized Basic EPS | -88.65 | -89.32 | -10.65 | -11.80 | -13.15 |
| EPS Diluted | -141.65 | -142.73 | -16.73 | -19.16 | -21.31 |
| Normalized Diluted EPS | -88.65 | -89.32 | -10.65 | -11.80 | -13.15 |
| Average Basic Shares Outstanding | 9.46M | 5.08M | 5.04M | 5.04M | 5.04M |
| Average Diluted Shares Outstanding | 9.46M | 5.08M | 5.04M | 5.04M | 5.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |